Melanotan II
Melanotan II risk profile, scheduling, and guidance for claims professionals and care workers .
Melanotan II is classified as Moderate risk (4 risk points) by AllMeds. NOT TGA registered. TGA has issued safety warnings. Cardiovascular and melanoma risks.
Key Takeaways
- Risk level: Moderate (4 points)
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | Unscheduled | Not PBS listed |
Risk Profile
NOT TGA registered. TGA has issued safety warnings. Cardiovascular and melanoma risks.
Regulatory and Compliance Guidance
When Melanotan II appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.
Australia TGA / PBS / State Schemes
Classified as Unscheduled under the Therapeutic Goods Administration (TGA).
Clinical Evidence
- TGA Safety Advisory: Melanotan-I and Melanotan-II (2020)
TGA warns Melanotan products are not approved in Australia. Reports of serious side effects including cardiovascular events, nausea, and changes to moles that could mask melanoma detection.
Official TGA safety warning — highly authoritative
- FDA Warning on Melanotan Products (2019)
FDA has warned consumers not to use Melanotan products. Not approved for any use. Concerns about melanoma risk.
Federal regulatory authority
- The dark side of tanning injections — ABC Investigations (2022)
Investigative reporting on Melanotan II use in Australia. Interviews with dermatologists warning about melanoma masking.
National broadcaster investigation
Need to assess this medication across your caseload?
Run a full risk assessment including Melanotan II interactions and compliance checks.
AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.
Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.